Closed-Loop Control,Artificial Intelligence–Based Decision-Support Systems,and Data Science

Phillip M , Nimri R , Bergenstal RM , et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr Rev, 2023; 44: 254–280.

Burnside MJ , Lewis DM , Crocket HR , et al. Open-source automated insulin delivery in type 1 diabetes. N Engl J Med, 2022; 387: 869–881.

Wadwa RP , Reed ZW , Buckingham BA , et al. Trial of hybrid closed-loop control in young children with type 1 diabetes. N Engl J Med, 2023; 388: 991–1001.

Bionic Pancreas Research Group; Russell SJ , Beck RW , et al. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med, 2022; 387: 1161–1172.

Boughton CK , Allen JM , Ware J , et al. Closed-loop therapy and preservation of C-peptide secretion in type 1 diabetes. N Engl J Med, 2022; 387: 882–893.

Choudhary P , Kolassa R , Keuthage W , et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diabetes Endocrinol, 2022; 10: 720–731.

Boughton CK , Hartnell S , Hobday N , et al. Implementation of fully closed-loop insulin delivery for inpatients with diabetes: real-world outcomes. Diabet Med, 2023; 40: e15092.

Pinsker JE , Dassau E , Deshpande S , et al. Outpatient randomized crossover comparison of zone model predictive control automated insulin delivery with weekly data driven adaptation versus sensor-augmented pump: results from the International Diabetes Closed-Loop Trial 4. Diabetes Technol Ther, 2022; 24: 635–642.

Daly AB , Boughton CK , Nwokolo M , et al. Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial. Nat Med, 2023; 29: 203–208.

Davis GM , Peters AL , Bode BW , et al. Safety and efficacy of the Omnipod 5 automated insulin delivery system in adults with type 2 diabetes: from injections to hybrid closed-loop therapy. Diabetes Care, 2023; 46: 742–750.

Chakrabarti A , Trawley S , Kubilay E , et al. Closed-loop insulin delivery effects on glycemia during sleep and sleep quality in older adults with type 1 diabetes: results from the ORACL Trial. Diabetes Technol Ther, 2022; 24: 666–671.

Flatt AJ , Peleckis AJ , Dalton-Bakes C , et al. Automated insulin delivery for hypoglycemia avoidance and glucose counterregulation in long-standing type 1 diabetes with hypoglycemia unawareness. Diabetes Technol Ther, 2023; 25: 302–314.

Lynch J , Kanapka LG , Russell SJ , et al. The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study: a multi-center single-arm evaluation of the insulin-only configuration of the bionic pancreas in adults and youth with type 1 diabetes. Diabetes Technol Ther, 2022; 24: 726–736.

Sherr JL , Bode BW , Forlenza GP , et al. Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: a single-arm multicenter clinical trial. Diabetes Care, 2022; 45: 1907–1910.

Garg SK , Grunberger G , Weinstock R , et al. Adult and pediatric MiniMed HCL outcomes 6-month RCT: HCL versus CSII control study group. improved glycemia with hybrid closed-loop versus continuous subcutaneous insulin infusion therapy: results from a randomized controlled trial. Diabetes Technol Ther, 2023; 25: 1–12.

Beck RW , Kanapka LG , Breton MD , et al. A meta-analysis of randomized trial outcomes for the t: slim X2 insulin pump with Control-IQ technology in youth and adults from age 2 to 72. Diabetes Technol Ther, 2023; 25: 329–342.

Michou P , Gkiourtzis N , Christoforidis A , Kotanidou EP , Galli-Tsinopoulou A. The efficacy of automated insulin delivery systems in children and adolescents with type 1 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract, 2023; 199: 110678.

Zeng B , Jia H , Gao L , Yang Q , Yu K , Sun F. Dual-hormone artificial pancreas for glucose control in type 1 diabetes: a meta-analysis. Diabetes Obes Metab, 2022; 24: 1967–1975.

Peacock S , Frizelle I , Hussain S. A systematic review of commercial hybrid closed-loop automated insulin delivery systems. Diabetes Ther. 2023; 14: 839–855.

Dermawan D , Kenichi Purbayanto MA. An overview of advancements in closed-loop artificial pancreas system. Heliyon, 2022; 8: e11648.

Nwokolo M , Hovorka R. The artificial pancreas and type 1 diabetes. J Clin Endocrinol Metab, 2023; 108: 1614–1623.

Karol AB , O'Malley G , Fallurin R , Levy CJ. Automated insulin delivery systems as a treatment for type 2 diabetes mellitus: a review. Endocr Pract, 2023; 29: 214–220.

Renard E. Automated insulin delivery systems: from early research to routine care of type 1 diabetes. Acta Diabetol, 2023; 60: 151–161.

Pease A , Callander E , Zomer E , et al. The cost of control: cost-effectiveness analysis of hybrid closed-loop therapy in youth. Diabetes Care, 2022; 45: 1971–1980.

Sherr JL , Heinemann L , Fleming GA , et al. Automated insulin delivery: benefits, challenges, and recommendations. a consensus report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetes Care, 2022; 45: 3058–3074.

Sherr JL , Heinemann L , Fleming GA , et al. Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetologia, 2023; 66: 3–22.

Rankin D , Hart RI , Kimbell B , et al. Rollout of closed-loop technology to pregnant women with type 1 diabetes: healthcare professionals’ views about potential challenges and solutions. Diabetes Technol Ther, 2023; 25: 260–269.

Kovatchev BP , Singh H , Mueller L , Gonder-Frederick LA. Biobehavioral changes following transition to automated insulin delivery: a large real-life database analysis. Diabetes Care. 2022; 45: 2636–2643.

Arrieta A , Battelino T , Scaramuzza AE , et al. Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: evidence from 12 870 real-world users. Diabetes Obes Metab, 2022; 24: 1370–1379.

Forlenza GP , Carlson AL , Galindo RJ , et al. Real-world evidence supporting tandem control-IQ hybrid closed-loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations. Diabetes Technol Ther, 2022; 24: 814–823.

Akturk HK , Snell-Bergeon J , Shah VN. Efficacy and safety of tandem control IQ without user-initiated boluses in adults with uncontrolled type 1 diabetes. Diabetes Technol Ther, 2022; 24: 779–783.

Benhamou PY , Adenis A , Lebbad H , et al. One-year real-world performance of the DBLG1 closed-loop system: data from 3706 adult users with type 1 diabetes in Germany. Diabetes Obes Metab, 2023; 25: 1607–1613.

Matejko B , Juza A , Kieć-Wilk B , et al. One-year follow-up of advance hybrid closed-loop system in adults with type 1 diabetes previously naive to diabetes technology: the effect of switching to a calibration-free sensor. Diabetes Technol Ther, 2023; 25: 554–558.

Lombardo F , Passanisi S , Alibrandi A , et al. MiniMed 780G six-month use in children and adolescents with type 1 diabetes: clinical targets and predictors of optimal glucose control. Diabetes Technol Ther, 2023; 25: 404–413.

Wang XS , Dunlop AD , McKeen JA , Feig DS , Donovan LE. Real-world use of Control-IQ technology automated insulin delivery in pregnancy: a case series with qualitative interviews. Diabet Med, 2023; 40: e15086.

Ware J , Allen JM , Boughton CK , et al. Hybrid closed-loop with faster insulin aspart compared with standard insulin aspart in very young children with type 1 diabetes: a double-blind, multicenter, randomized, crossover study. Diabetes Technol Ther, 2023; 25: 431–436.

Lachal S , Tourki Y , Franc S , Huneker E , Charpentier G , Benhamou PY. Hybrid closed-loop control with ultrarapid lispro compared with standard insulin aspart and faster insulin aspart: an in silico study. J Diabetes Sci Technol, 2023; 17: 176–185.

Beck RW , Russell SJ , Damiano ER , et al. A multicenter randomized trial evaluating fast-acting insulin aspart in the bionic pancreas in adults with type 1 diabetes. Diabetes Technol Ther, 2022; 24: 681–696.

Pasqua MR , Jafar A , Kobayati A , Tsoukas MA , Haidar A. Low-dose empagliflozin as adjunct to hybrid closed-loop insulin therapy in adults with suboptimally controlled type 1 diabetes: a randomized crossover controlled trial. Diabetes Care, 2023; 46: 165–172.

Hughes MS , Kingman RS , Hsu L , Lal RA , Buckingham BA , Zaharieva DP. Swimming with the Omnipod 5 automated insulin delivery system: connectivity in the water. Diabetes Care, 2023; 46: e148–e150.

Brown SA. On the path toward expanding treatment options for diabetes. N Engl J Med, 2022; 387: 935–936.

Scaramuzza AE , Cherubini V , Rabbone I. Open-source automated insulin delivery in type 1 diabetes. N Engl J Med, 2022; 387: 2006–2007.

Brown SA , Kovatchev BP , Raghinaru D , et al; iDCL Trial Research Group. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med, 2019; 381: 1707–1717.

Breton MD , Kanapka LG , Beck RW , et al; iDCL Trial Research Group. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med, 2020; 383: 836–845.

Nimri R , Phillip M , Kovatchev B. Decision support systems and closed-loop. Diabetes Technol Ther, 2022; 24 (Suppl 1): S58–S75.

Huang S , Liang Y , Li J , Li XJ. Clinical decision support systems (CDSSs) in diabetes management—a scoping review. Diabetes, 2023; 72 (Suppl 1): 1055-P.

Ahmed A , Aziz S , Abd-Alrazaq A , Farooq A , Sheikh J. Overview of artificial intelligence-driven wearable devices for diabetes: scoping review. J Med Internet Res, 2022; 24: e36010.

Lee YB , Kim G , Jun JE , et al. An integrated digital health care platform for diabetes management with AI-based dietary management: 48-week results from a randomized controlled trial. Diabetes Care, 2023; 46: 959–966.

Lupidi M , Danieli L , Fruttini D , et al. Artificial intelligence in diabetic retinopathy screening: clinical assessment using handheld fundus camera in a real-life setting. Acta Diabetol, 2023; 60: 1083–1088.

Bersoux S , Cook CB , Kongable GL , Shu J , Zito DR. Benchmarking glycemic control in U.S. hospitals. Endocr Pract, 2014; 20: 876–883.

Pichardo-Lowden A , Umpierrez G , Lehman EB , et al. Clinical decision support to improve management of diabetes and dysglycemia in the hospital: a path to optimizing practice and outcomes. BMJ Open Diabetes Res Care, 2021; 9: e001557.

Karges B , Schwandt A , Heidtmann B , et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA, 2017; 318: 1358–1366.

Bisio A , Anderson S , Norlander L , et al. Impact of a novel diabetes support system on a cohort of individuals with type 1 diabetes treated with multiple daily injections: a multicenter randomized study. Diabetes Care, 2022; 45: 186–193.

El Fathi A , Palisaitis E , von Oettingen JE , et al. A pilot non-inferiority randomized controlled trial to assess automatic adjustments of insulin doses in adolescents with type 1 diabetes on multiple daily injections therapy. Pediatr Diabetes, 2020; 21: 950–959.

Fang M , Wang D , Coresh J , Selvin E. Trends in diabetes treatment and control in U.S. adults, 1999–2018. N Engl J Med, 2021; 384: 2219–2228.

Garg S. Top 30 ChatGPT alternatives that will blow your mind in 2023 (free & paid). Writesonic, August 20, 2023. https://writesonic.com/blog/chatgpt-alternatives/.

Sharma S , Pajai S , Prasad R , et al. A critical review of ChatGPT as a potential substitute for diabetes educators. Cureus, 2023; 15: e38380.

Huang C , Chen L , Huang H , et al. Evaluate the accuracy of ChatGPT's responses to diabetes questions and misconceptions. Transl Med, 2023; 21: 502.

Nakhleh A , Spitzer S , Shehadeh N. ChatGPT's response to the diabetes knowledge questionnaire: implications for diabetes education. Diabetes Technol Ther, 2023; 25: 571–573.

Bailey R , Calhoun P , Bergenstal RM , et al. Assessment of the glucose management indicator using different sampling durations. Diabetes Technol Ther, 2023; 25: 148–150.

Monzon AD , Patton SR , Clements M. An examination of the glucose management indicator in young children with type 1 diabetes. J Diabetes Sci Technol, 2022; 16: 1505–1512.

Akturk HK , Herrero P , Oliver N , et al. Impact of different types of data loss on optimal continuous glucose monitoring sampling duration. Diabetes Technol Ther, 2022; 24: 749–753.

Xu Y , Bergenstal RM , Dunn TC , et al. Interindividual variability in average glucose-glycated haemoglobin relationship in type 1 diabetes and implications for clinical practice. Diabetes Obes Metab, 2022; 24: 1779–1787.

Shah VN , Vigers T , Pyle L , et al. Discordance between glucose management indicator and glycated hemoglobin in people without diabetes. Diabetes Technol Ther, 2023; 25: 324–328.

Dunn TC , Xu Y , Bergenstal RM , et al. Personalized glycated hemoglobin in diabetes management: closing the gap with glucose management indicator. Diabetes Technol Ther, 2023; 25(Suppl 3): S65–S74.

Shah VN. Limitations of reporting time below range as a percentage. Diabetes Technol Ther. Published online August 18, 2023. doi: 10.1089/dia.2023.0247.

Schiavon M , Galderisi A , Basu A , et al. A new index of insulin sensitivity from glucose sensor and insulin pump data: in silico and in vivo validation in youths with type 1 diabetes. Diabetes Technol Ther, 2023; 25: 270–278.

Espinoza JC , Yeung AM , Huang J , et al. The need for data standards and implementation policies to integrate insulin delivery data into the electronic health record. J Diabetes Sci Technol, 2023; 17: 1376–1386.

Espinoza J , Xu NY , Nguyen KT , et al. The need for data standards and implementation policies to integrate CGM data into the electronic health record. J Diabetes Sci Technol, 2023; 17: 495–502.

Xu NY , Nguyen KT , DuBord AY , et al. The launch of the iCoDE standard project. J Diabetes Sci Technol, 2022; 16: 887–895.

Yeung AM , Huang J , Klonoff DC , et al. iCoDE June 22, 2022 Steering Committee meeting summary report. J Diabetes Sci Technol, 2022; 16: 1575–1576.

Espinoza J , Klonoff D , Vidmar A , et al. 2022 iCoDE Report: CGM-EHR Integration Standards and Recommendations. Diabetes Technology Society; November 7, 2022. https://www.diabetestechnology.org/icode/.

Zaharieva DP , Senanayake R , Brown C , et al. Adding glycemic and physical activity metrics to a multimodal algorithm-enabled decision-support tool for type 1 diabetes care: keys to implementation and opportunities. Front Endocrinol (Lausanne), 2022; 13: 1096325.

Sly B , Russell AW , Sullivan C. Digital interventions to improve safety and quality of inpatient diabetes management: a systematic review. Int J Med Inform, 2022; 157: 104596.

Gerwer JE , Bacani G , Juang PS , et al. Electronic health record-based decision-making support in inpatient diabetes management. Curr Diab Rep, 2022; 22: 433–440.

Bergenstal RM , Simonson GD , Heinemann L. More green, less red: how color standardization may facilitate effective use of CGM data. J Diabetes Sci Technol, 2022; 16: 3–6.

Huang J , Yeung AM , Armstrong DG , et al. Artificial intelligence for predicting and diagnosing complications of diabetes. J Diabetes Sci Technol, 2023; 17: 224–238.

Sheer R , Nair R , Pasquale MK , et al. Predictive risk models to identify patients at high-risk for severe clinical outcomes with chronic kidney disease and type 2 diabetes. J Prim Care Community Health, 2022; 13: 21501319211063726.

Karalliedde J , French O , Burnhill G , et al. A pragmatic digital health informatics based approach for aiding clinical prioritisation and reducing backlog of care: a study in cohort of 4022 people with diabetes. Diabetes Res Clin Pract, 2023; 203: 110834.

Cheheltani R , King N , Lee S , et al. Predicting misdiagnosed adult-onset type 1 diabetes using machine learning. Diabetes Res Clin Pract, 2022; 191: 110029.

Mosquera-Lopez C , Ramsey KL , Roquemen-Echeverri V , et al. Modeling risk of hypoglycemia during and following physical activity in people with type 1 diabetes using explainable mixed-effects machine learning. Comput Biol Med, 2023; 155: 106670.

Ren Y , Loftus TJ , Datta S , et al. Performance of a machine learning algorithm using electronic health record data to predict postoperative complications and report on a mobile platform. JAMA Netw Open, 2022; 5: e2211973.

Williams DD , Ferro D , Mullaney C , et al. Development of an “all-data-on-hand” deep learning model to predict hospitalization for diabetic ketoacidosis (DKA) in youth with type 1 diabetes (T1D). JMIR Diabetes, 2023; 8: e47592.

Fabris C , Heinemann L , Beck R , et al. Estimation of hemoglobin A1c from continuous glucose monitoring data in individuals with type 1 diabetes: is time in range all we need?. Diabetes Technol Ther, 2020; 22: 501–508.